Patheon, a global provider of drug development and manufacturing services, has announced the expansion of services utilizing a new Intermediate Scale Processing Suite (ISPS) at its Cincinnati facility in Reading.
According to Patheon, the ISPS provides increased manufacturing capacity that will bridge the gap between the company's development and commercial scale facilities.
The expansion of services will also help to develop robust processes as projects move from development to commercial using statistical design of experiments, to support the
FDA's Quality by Design initiative.
"The ISPS provides us with another valuable service to address the unique needs of our customers," says Terry Novak, president of North American operations and chief marketing officer for Patheon. "By adding this equipment we will be able to reduce time and resources it takes to moving a new product though development."
Read the full release
here.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.